Transforming Growth Factor Alpha in Breast Tumors
Author Information
Author(s): H. Gregory, C.E. Thomas, I.R. Willshire, J.A. Young, H. Anderson, A. Baildam, A. Howell
Primary Institution: ICI Pharmaceuticals and Christie Hospital
Hypothesis
Does the secretion of TGF-a and URO-EGF differ in the urine of cancer patients compared to controls?
Conclusion
The study found no significant difference in TGF-a levels in urine between breast cancer patients and controls, but TGF-a levels in tumors were significantly reduced after treatment with tamoxifen.
Supporting Evidence
- Urine samples from breast cancer patients showed TGF-a levels ranging from 0 to 61.5 ng/24h.
- Steroid receptor positive tumors had a mean TGF-a level of 14.8 ng/g tissue.
- Tamoxifen treatment resulted in a significant reduction of TGF-a levels in tumors.
Takeaway
The researchers looked at a substance called TGF-a in the urine of breast cancer patients and found it was similar to healthy people, but treatment with a drug called tamoxifen lowered TGF-a in tumors.
Methodology
The study used radioimmunoassays and mitogenic assays to evaluate TGF-a content in tumor and urine samples from breast cancer patients and controls.
Limitations
The study had a small sample size and may not represent all breast cancer patients.
Participant Demographics
Breast cancer patients and age-matched controls.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website